"SubQ" and "IM" describe *where* an injection is placed — which tissue layer — and that placement changes how the compound is absorbed. This is general pharmacology, not administration instruction.

In plain terms: same needle, different depth — and depth changes the shape of the level curve.

The two layers

  • Subcutaneous (SubQ): the fatty layer just beneath the skin. Less vascular, so absorption is typically slower and steadier2.
  • Intramuscular (IM): into muscle, deeper down. Muscle is more vascular, so IM tends to absorb faster, reaching a higher, earlier peak2.
SubQIM
Target tissueFat under skinMuscle
Typical absorptionSlower, steadierFaster
Curve shapeFlatter peakHigher, earlier peak
Common in research forMany peptides, GLP-1sSome oil-based esters

What a head-to-head study found

Because both routes are used clinically, some studies compare them directly for the same molecule:

Study (cited)ModelKey resultYear
Ortega et al.1Human PK (mepolizumab)SubQ and IM gave broadly similar total exposure; IM absorbed to a higher, earlier peak, matching the "more vascular = faster" principle2014

In plain terms: for that molecule, the *amount* absorbed was similar either way, but IM got there faster and higher — exactly what the tissue biology predicts.

Why route shows up in protocols

Absorption rate influences the shape of the level curve — a faster-absorbing route produces an earlier, higher peak. That is why research protocols specify a route, and why the medication-level curves implicitly assume one. Route is part of the pharmacokinetic picture alongside concentration and half-life.

Practical companions

The mechanics of placing a SubQ dose are in how to draw a subcutaneous injection, and rotating placement in injection site rotation.

This describes absorption pharmacology, not a recommendation of route, technique, or dose — those belong to a clinician and the relevant product guidance.